Peptide
Teriparatide (Forteo)
Teriparatide (brand name Forteo) is a recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). It was FDA-approved in November 2002 as the first anabolic agent for osteoporosis treatment. Unlike antiresorptive drugs, teriparatide stimulates new bone formation. It is indicated for postmenopausal women and men with osteoporosis at high fracture risk, and for glucocorticoid-induced osteoporosis.
- Updated
- How we grade
- 49 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 3
- Outcomes
- 13
- Graded outcomes
- 6412
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
- Bone Mineral Density: improves
- Safety/Tolerability: improves
- Anti-Cancer Activity: improves
Bone Health
- Bone Formation Markers: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Bone Formation Markers Large Increase | Improves (the measure goes up) | Large effect | 3 studies | |||
Studies that measured bone formation markers
| ||||||
Key findings
- Glucocorticoid-Induced OsteoporosisImproves (the measure goes up)
- Femoral Neck BMDImproves (the measure goes up)
- Lumbar Spine BMDImproves (the measure goes up)
Safety notes in the studies
- Meta-analysis showed 70% reduction in vertebral fracture risk (RR 0.30, 95% CI: 0.21-0.44).
- Meta-analysis showed 38% reduction in non-vertebral fracture risk (RR 0.62, 95% CI: 0.44-0.87) in postmenopausal women with osteoporosis.
Studies cited
49 studies from PubMed
- Long-term impact of teriparatide on bone mineral density, trabecular bone score, and fracture risk relative to total hip T-score: A two-decade, registry-based cohort study
- Real-world safety and effectiveness of romosozumab following daily or weekly administration of teriparatide in primary and secondary osteoporosis.
- Prolonged hypercalcemia induced by teriparatide: a case report and literature review.
- The Fracture Incidence and Safety of Teriparatide and Bisphosphonate in Postmenopausal Women With Osteoporosis: A Meta-Analysis.
- Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.
- Delayed and significant hypercalcaemia due to teriparatide therapy: a case report and review.
- Protective effect of teriparatide against vancomycin-induced cytotoxicity in osteoblasts.
- Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study.
- Potential effects of teriparatide (PTH (1-34)) on osteoarthritis: a systematic review.
- Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
- Teriparatide induces angiogenesis in ischemic cerebral infarction zones of rats through AC/PKA signaling and reduces ischemia-reperfusion injury.
- Teriparatide therapy for medication-related osteonecrosis of the jaw: case report and literature review.
- Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study.
- Assessment of the efficacy of teriparatide treatment for osteoporosis on lumbar fusion surgery outcomes: a systematic review and meta-analysis.
- Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis.
- The Efficacy of Teriparatide in Improving Fracture Healing in Hip Fractures: A Systematic Review and Meta-Analysis.
- Teriparatide and bisphosphonate use in osteoporotic spinal fusion patients: a systematic review and meta-analysis.
- Effect of teriparatide use on bone mineral density and spinal fusion: a narrative review of animal models.
- Is Teriparatide Beneficial to Spinal Fusion Surgery in the Older Patient?: A Narrative Review.
- Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis.
- The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years.
- Fracture Risk Following Discontinuation of Teriparatide: A Review of the Literature.
- Bone Mineral Density Response from Teriparatide in Patients with Osteoporosis
- Teriparatide attenuates scarring around murine cranial bone allograft via modulation of angiogenesis.
- Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials.
- Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis.
- Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma.
- Effectiveness of Teriparatide on Fracture Healing: A Systematic Review and Meta-Analysis.
- A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.
- Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis.
- Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials
- Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk
- A fracture does not adversely affect bone mineral density responses after teriparatide treatment
- Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study
- Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study
- Teriparatide: a review of its use in osteoporosis.
- Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review.
- Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
- Teriparatide for severe osteoporosis.
- Teriparatide (Forteo) for osteoporosis.
- A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
- Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
- Teriparatide for postmenopausal osteoporosis.
- Teriparatide: A bone formation treatment for osteoporosis.
- Treatment of osteoporosis with Teriparatide rhPTH(1-34).
- Teriparatide: a review.
- Teriparatide (forteo) for osteoporsis.
- Forteo approved for osteoporosis treatment.
- Recombinant human PTH 1-34 (Forteo): an anabolic drug for osteoporosis.